Unum drops an­oth­er pro­gram for trou­bled PhI ther­a­py, mov­ing its eggs to the sol­id tu­mor bas­ket

Sev­er­al months af­ter Unum Ther­a­peu­tics ran in­to a sec­ond safe­ty cri­sis sur­round­ing its pre­mier Phase I ther­a­py, the biotech is putting an­oth­er AC­TR087 tri­al to bed.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA